

VASTox plc
(“VASTox” or “the Company”)

**VASTOX ANNOUNCES SIGNIFICANT PROGRESS IN
PHARMACEUTICAL SERVICES BUSINESS**

- **Pilot screening deals signed in zebrafish platform with top tier pharmaceutical companies worth in excess of €300,000**
- **Completion of carbohydrate chemistry GMP clinical scale-up facility**

Oxford, UK, 27 June 2007 – VASTox plc (AIM: VOX), a leading UK biotechnology company, announces that it has entered into a series of pilot screening agreements with major pharmaceutical companies, including Merck KGaA, Johnson & Johnson (Pharmaceutical Research & Development, Belgium) and Servier. Together, the deals are worth in excess of €300,000 in service revenues to VASTox during 2007.

VASTox will use its market-leading zebrafish technology platform to blind-screen selections of known compounds for safety and toxicity to validate to its clients how this technology can predict unwanted side effects. It is the Company's aim to develop these relationships into higher-value, longer-term partnerships.

A strategy of internal growth and focused acquisitions over the past 18 months has seen VASTox assemble the most advanced and extensive zebrafish technology platform in the world. This versatile organism is proving highly valuable in drug discovery because it can be used to predict the safety of potential drug candidates as well as to develop a wide range of models of human diseases including neuro-disorders and regenerative medicine, therapeutic areas in which VASTox has drug discovery programmes.

Completion of GMP Facility

VASTox also announces today that it has completed, on-time and on-budget, the construction of its GMP facility located at its subsidiary company, Dextra Laboratories, which specialises in carbohydrate chemistry. The GMP facility will allow VASTox to produce material in sufficient quantities for use in human clinical trials up to the Phase II stage of clinical development.

In order to ensure the facility is fully GMP compliant, VASTox will perform a test run to produce material for one of its own drug discovery programmes with the facility receiving its first fee-paying client by the end of July 2007.

Steven Lee, PhD, CEO of VASTox commented: “The zebrafish is emerging as a valuable and powerful tool within drug discovery and VASTox is the world's leader in the use of this organism. The signing of these pilot deals means VASTox has now worked with seven of the ten largest pharmaceutical companies, which provides continued recognition of our technology and an opportunity to further validate this exciting technology platform.”

He added: “The completion of the GMP laboratory is a key milestone for our pharmaceutical service offering. Carbohydrate chemistry is becoming increasingly important in the search for and development of effective new drugs and our Dextra

subsidiary is already established as a leading force in this field. With GMP accreditation, VASTox can now offer its partners and customers the highest quality carbohydrate chemistry services from discovery through to clinical development.”

- ends -

For more information please contact:

VASTox

Steven Lee, PhD, Chief Executive Officer

Tel: +44 (0)1235 443951

Darren Millington, ACMA, Chief Financial Officer

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot

Tel: +44 (0)207 071 4300

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.